|
|
Contents
|
|
|
EXTERNAL SECTIONS
■
IMAGING
■ LIQUID
BIOPSY
■ POSITRON
EMISSION TOMOGRAPHY
■
RADIOMICS
|
Overview
|
|
|
|
BIOMARKERS
|
|
|
Alameda F, Velarde JM, Carrato C, Vidal N, Arumí M, Naranjo
D, Martinez-Garcia M, Ribalta T, Balañá C.
Prognostic value of stem cell markers in glioblastoma.
Biomarkers. 2019 Nov;24(7):677-683. doi:
10.1080/1354750X.2019.1652345. Epub 2019 Sep 8.
Source
.
Similar
articles
|
|
|
.
|
Loo HK, Mathen P, Lee J, Camphausen K.
Circulating
biomarkers for high-grade glioma.
Biomark Med. 2019
Feb;13(3):161-165. doi: 10.2217/bmm-2018-0463. Epub 2019 Feb 26.
Source
| Full
text | Similar
articles
|
|
|
|
Vaios
EJ, Nahed BV, Muzikansky A, Fathi AT, Dietrich J.
Bone
marrow response as a potential biomarker of outcomes in
glioblastoma patients.
J
Neurosurg. 2016 Oct 14:1-7. [Epub ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Vietheer
JM, Rieger J, Wagner M, Senft C, Tichy J, Foerch C.
Serum
concentrations of glial fibrillary acidic protein (GFAP) do not
indicate tumor recurrence in patients with glioblastoma.
J
Neurooncol. 2017 Jul 17. doi: 10.1007/s11060-017-2565-y. [Epub
ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
CIRCULATING
TUMOR CELLS
|
|
|
|
TUMOR
STEM CELLS
|
|
.
|
van Schaijik B, Wickremesekera AC, Mantamadiotis T, Kaye AH, Tan
ST, Stylli SS, Itinteang T.
Circulating tumor stem cells
and glioblastoma: A review.
J Clin Neurosci. 2019
Mar;61:5-9. doi: 10.1016/j.jocn.2018.12.019. Epub 2019 Jan 6.
Source
| Full
text | Similar
articles
|
|
|
Ki-67
LABELING INDEX
|
|
.
|
Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA.
Ki-67
labeling index in glioblastoma; does it really matter?
Hematol
Oncol Stem Cell Ther. 2018 Dec 8. pii: S1658-3876(18)30115-8. doi:
10.1016/j.hemonc.2018.11.001. [Epub
ahead of print]
Source
| Full
text | Similar
articles
|
|
|
CEREBELLAR
GLIOBLASTOMA
|
|
|
Kikuchi
K, Hiratsuka Y, Kohno S, Ohue S, Miki H, Mochizuki T.
Radiological
features of cerebellar glioblastoma.
J
Neuroradiol. 2016 Jul;43(4):260-5. doi:
10.1016/j.neurad.2015.10.006. Epub 2015 Dec 28.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
IMAGING
|
|
|
Chiang
S.
Follow-Up
Imaging: Molecular Imaging is Likely Best as a Single Modality,
but Multimodality Imaging is the Future.
Front
Neurol. 2015 Apr 24;6:74. doi: 10.3389/fneur.2015.00074.
eCollection 2015. Review. No abstract available.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
.
|
Coburger J, Segovia von Riehm J, Ganslandt O, Wirtz CR, Renovanz
M.
Is There an Indication for Intraoperative MRI in
Subtotal Resection of Glioblastoma? A Multicenter Retrospective
Comparative Analysis.
World Neurosurg. 2017 Nov 11. pii:
S1878-8750(17)31934-4. doi: 10.1016/j.wneu.2017.11.015. [Epub
ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
|
Galldiks
N, Langen KJ.
Amino
Acid PET - An Imaging Option to Identify Treatment Response,
Posttherapeutic Effects, and Tumor Recurrence?
Front
Neurol. 2016 Jul 28;7:120. doi: 10.3389/fneur.2016.00120.
eCollection 2016.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Henker
C, Kriesen T, Glass Ä, Schneider B, Piek J.
Volumetric
quantification of glioblastoma: experiences with different
measurement techniques and impact on survival.
J
Neurooncol. 2017 Jul 28. doi: 10.1007/s11060-017-2587-5. [Epub
ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Huang
RY, Neagu MR, Reardon DA, Wen PY.
Pitfalls
in the neuroimaging of glioblastoma in the era of antiangiogenic
and immuno/targeted therapy - detecting illusive disease, defining
response.
Front
Neurol. 2015 Feb 23;6:33. doi: 10.3389/fneur.2015.00033.
eCollection 2015.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Kolakshyapati
M, Adhikari RB, Karlowee V, Takayasu T, Nosaka R, Amatya VJ,
Takeshima Y, Akiyama Y, Sugiyama K, Kurisu K, Yamasaki F.
Nonenhancing
peritumoral hyperintense lesion on diffusion-weighted imaging in
glioblastoma: a novel diagnostic and specific prognostic
indicator.
J
Neurosurg. 2017 Mar 31:1-12. doi: 10.3171/2016.10.JNS161694. [Epub
ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
New
PZ, Rosenfeld MR.
Editorial:
Pitfalls in the Neuro-Imaging of Glioblastoma in the Era of
Antiangiogenic and Immune-Targeted Therapy-Detecting Elusive
Disease, Defining Response.
Front
Neurol. 2017 Jul 3;8:311. doi: 10.3389/fneur.2017.00311.
eCollection 2017.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Wong
KK, Fung SH, New PZ, Wong ST.
Technical
Pitfalls of Signal Truncation in Perfusion MRI of Glioblastoma.
Front
Neurol. 2016 Aug 2;7:121. doi: 10.3389/fneur.2016.00121.
eCollection 2016.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
FLAIR
IMAGING
|
|
|
Chang
PD, Chow DS, Yang PH, Filippi CG, Lignelli A.
Predicting
Glioblastoma Recurrence by Early Changes in the Apparent Diffusion
Coefficient Value and Signal Intensity on FLAIR Images.
AJR
Am J Roentgenol. 2017 Jan;208(1):57-65. doi: 10.2214/AJR.16.16234.
Epub 2016 Oct 11.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Lasocki
A, Gaillard F, Tacey M, Drummond K, Stuckey S.
Multifocal
and multicentric glioblastoma: Improved characterisation with
FLAIR imaging and prognostic implications.
J
Clin Neurosci. 2016 Jun 21. pii: S0967-5868(16)00143-0. doi:
10.1016/j.jocn.2016.02.022. [Epub ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
MAGNETIC
RESONANCE IMAGING
|
|
|
Jovanovic M, Radenkovic S, Stosic-Opincal T, Lavrnic S, Gavrilovic
S, Lazovic-Popovic B, Soldatovic I, Maksimovic R.
Differentiation
between progression and pseudoprogresion by arterial spin labeling
MRI in patients with glioblastoma multiforme.
J BUON.
2017 Jul-Aug;22(4):1061-1067.
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
|
Lasocki
A, Tsui A, Gaillard F, Tacey M, Drummond K, Stuckey S.
Reliability
of noncontrast-enhancing tumor as a biomarker of IDH1 mutation
status in glioblastoma.
J
Clin Neurosci. 2017 May;39:170-175. doi:
10.1016/j.jocn.2017.01.007. Epub 2017 Feb 14.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Ravikanth
R.
Advanced
Magnetic Resonance Imaging of Glioblastoma Multiforme.
J
Neurosci Rural Pract. 2017 Jul-Sep;8(3):439-440. doi:
10.4103/jnrp.jnrp_423_16.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
Reliability
in Recurrent Glioblastoma
|
|
.
|
Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry
RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL.
Interreader
Variability of Dynamic Contrast-enhanced MRI of Recurrent
Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.
Radiology. 2019 Feb;290(2):467-476. doi:
10.1148/radiol.2019181296. Epub 2018 Nov 27.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Wolf RL.
MRI of Recurrent Glioblastoma: Reliability and
Reality.
Radiology. 2019 Feb;290(2):477-478. doi:
10.1148/radiol.2018182530. Epub 2018 Nov 27.
Comment
on: Barboriak
DP et
al, Interreader Variability of Dynamic Contrast-enhanced MRI of
Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625
Study. Radiology. 2019 Feb;290(2):467-476. doi:
10.1148/radiol.2019181296. Epub 2018 Nov 27. Source
|
Full
text
Source
| Full
text |
Similar
articles
|
|
|
C11
METHIONINE PET
|
|
.
|
Wang Y, Rapalino O, Heidari P, Loeffler J, Shih HA, Oh K, Mahmood
U.
C11 Methionine PET (MET-PET) Imaging of Glioblastoma
for Detecting Post-operative Residual Disease and Response to
Chemoradiation Therapy.
Int J Radiat Oncol Biol Phys.
2018 Jun 15. pii: S0360-3016(18)30964-7. doi:
10.1016/j.ijrobp.2018.06.011. [Epub ahead of print]
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
Extracranial
metastasis
|
|
|
Garcia
JR, Corbella C, Baquero M, Bassa P, Soler M.
Extracranial
metastasis of multiforme glioblastoma detected by 11C-methionine
brain PET/CT.
Rev
Esp Med Nucl Imagen Mol. 2016 Oct 19. pii: S2253-654X(16)30066-X.
doi: 10.1016/j.remn.2016.08.004. [Epub ahead of print] English,
Spanish.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
18F-DOPA
PET/CT
|
|
.
|
Humbert O, Bourg V, Mondot L, Gal J, Bondiau PY, Fontaine D,
Saada-Bouzid E, Paquet M, Chardin D, Almairac F, Vandenbos F,
Darcourt J.
18F-DOPA PET/CT in brain
tumors: impact on multidisciplinary brain tumor board decisions.
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):558-568. doi:
10.1007/s00259-018-4240-8. Epub 2019 Jan 5.
Source
| Full
text | Similar
articles
|
|
|
68Ga-PSMA
PET/CT
|
|
|
Kunikowska J, Bartosz K, Leszek K.
Glioblastoma
multiforme: another potential application for 68Ga-PSMA
PET/CT as a guide for targeted therapy.
Eur J Nucl Med
Mol Imaging. 2018 Jan 31. doi: 10.1007/s00259-018-3934-2. [Epub
ahead of print]
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
.
|
Salas Fragomeni RA, Menke JR, Holdhoff M, Ferrigno C, Laterra JJ,
Solnes LB, Javadi MS, Szabo Z, Pomper MG, Rowe SP.
Prostate-Specific Membrane Antigen-Targeted Imaging With
[18F]DCFPyL in High-Grade Gliomas.
Clin Nucl Med. 2017
Oct;42(10):e433-e435. doi: 10.1097/RLU.0000000000001769.
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
PRESENTING
SYMPTOMS
|
|
.
|
Dührsen L, Sauvigny T, Ricklefs FL, Mende KC, Schaper M,
Matschke J, Goebell E, Westphal M, Martens T.
Seizures as
presenting symptom in patients with glioblastoma.
Epilepsia.
2019 Jan;60(1):149-154. doi: 10.1111/epi.14615.
Epub 2018 Dec 9.
Source
| Full
text | Similar
articles
|
|
|
SUBTYPES
|
|
|
Chakraborty
S, Priamo F, Boockvar JA.
Magnetic
Resonance Imaging to Identify Glioblastoma Molecular Phenotypes.
Neurosurgery.
2016 Feb;78(2):N20-1. doi: 10.1227/01.neu.0000479895.10242.9d.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Itakura
H, Achrol AS, Mitchell LA, Loya JJ, Liu T, Westbroek EM, Feroze
AH, Rodriguez S, Echegaray S, Azad TD, Yeom KW, Napel S, Rubin DL,
Chang SD, Harsh GR 4th, Gevaert O.
Magnetic
resonance image features identify glioblastoma phenotypic subtypes
with distinct molecular pathway activities.
Sci
Transl Med. 2015 Sep 2;7(303):303ra138. doi:
10.1126/scitranslmed.aaa7582.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
.
|
Mahlokozera T, Vellimana AK, Li
T, Mao DD, Zohny ZS, Kim DH, Tran DD, Marcus DS, Fouke SJ, Campian
JL, Dunn GP, Miller CA, Kim AH.
Biological and
therapeutic implications of multisector sequencing in newly
diagnosed glioblastoma.
Neuro Oncol. 2018 Mar
27;20(4):472-483. doi: 10.1093/neuonc/nox232.
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
.
|
Nassiri F, Aldape K, Zadeh G.
The multiforme of
glioblastoma.
Neuro Oncol. 2018 Mar 27;20(4):437-438.
doi: 10.1093/neuonc/noy025.
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
Newly
diagnosed tumors
|
|
|
|
BCNU
WAFERS
|
|
|
Murai
S, Ichikawa T, Kurozumi K, Shimazu Y, Oka T, Otani Y, Shimizu T,
Date I.
Quantitative
analysis of brain edema in patients with malignant glioma treated
with BCNU wafers.
J
Clin Neurosci. 2016 Jul 21. pii: S0967-5868(16)30381-2. doi:
10.1016/j.jocn.2016.03.042. [Epub ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
BIOPSY
|
|
|
Staller
A.
Presumed
Glioblastoma Multiforme: A Case for Biopsy Prior to Treatment.
Clin
J Oncol Nurs. 2016 Feb;20(1):95-7. doi: 10.1188/16.CJON.95-97.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
IMAGING
|
|
|
Toh
CH, Castillo M.
Early-Stage
Glioblastomas: MR Imaging-Based Classification and Imaging
Evidence of Progressive Growth.
AJNR
Am J Neuroradiol. 2016 Nov 17. [Epub ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
PROGRESSION
AND PSEUDOPROGRESSION
|
|
|
Wick
W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F,
Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T.
Evaluation
of pseudoprogression rates and tumor progression patterns in a
phase III trial of bevacizumab plus radiotherapy/temozolomide for
newly diagnosed glioblastoma.
Neuro
Oncol. 2016 Aug 11. pii: now091. [Epub ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
SERUM
miRNAs
|
|
|
Regazzo
G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L,
Sperati F, Villani V, Carapella C, Piaggio G, Pelosi A, Rizzo MG.
A
restricted signature of serum miRNAs distinguishes glioblastoma
from lower grade gliomas.
J
Exp Clin Cancer Res. 2016 Jul 30;35(1):124. doi:
10.1186/s13046-016-0393-0.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
Recurrent
tumors
|
|
|
|
BEVACIZUMAB
|
|
|
Barajas
RF Jr, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, Cha
S.
The
Development of Reduced Diffusion Following Bevacizumab Therapy
Identifies Regions of Recurrent Disease in Patients with
High-grade Glioma.
Acad
Radiol. 2016 Sep;23(9):1073-82. doi: 10.1016/j.acra.2016.04.004.
Epub 2016 Jul 18.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Bertaut
A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V,
Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL,
Boidot R, Ghiringhelli F.
Blood
baseline neutrophil count predicts bevacizumab efficacy in
glioblastoma.
Oncotarget.
2016 Jul 28. doi: 10.18632/oncotarget.10898. [Epub ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Nguyen
HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz
CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS.
Progressing
Bevacizumab-Induced Diffusion Restriction Is Associated with
Coagulative Necrosis Surrounded by Viable Tumor and Decreased
Overall Survival in Patients with Recurrent Glioblastoma.
AJNR
Am J Neuroradiol. 2016 Aug 4. [Epub ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
IMAGING
FOR DETECTION OF RECURRENCE / PROGRESSION
|
|
|
|
OVERVIEW
|
|
.
|
Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S,
Argyropoulou MI.
Radiation Necrosis, Pseudoprogression,
Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the
Evaluation of Treated Gliomas.
Contrast Media Mol
Imaging. 2018 Dec 2;2018:6828396. doi: 10.1155/2018/6828396.
eCollection 2018.
Source
| Full
text | Similar
articles
|
|
|
MRI
|
|
|
Ellingson
BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ.
Pseudoprogression,
radionecrosis, inflammation or true tumor progression? challenges
associated with glioblastoma response assessment in an evolving
therapeutic landscape.
J
Neurooncol. 2017 Apr 5. doi: 10.1007/s11060-017-2375-2. [Epub
ahead of print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Yoo
RE, Choi SH, Kim TM, Park CK, Park SH, Won JK, Kim IH, Lee ST,
Choi HJ, You SH, Kang KM, Yun TJ, Kim JH, Sohn CH.
Dynamic
contrast-enhanced MR imaging in predicting progression of
enhancing lesions persisting after standard treatment in
glioblastoma patients: a prospective study.
Eur
Radiol. 2016 Dec 14. [Epub ahead of print] DOI:
10.1007/s00330-016-4692-9.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
MULTIPARAMETRIC
MRI
|
|
|
Nael K, Bauer AH, Hormigo A, Lemole M, Germano IM, Puig J, Stea B.
Multiparametric MRI for Differentiation of Radiation
Necrosis From Recurrent Tumor in Patients With Treated
Glioblastoma.
AJR Am J Roentgenol. 2017 Sep 27:1-6. doi:
10.2214/AJR.17.18003. [Epub ahead of print]
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
PET
AND PET/CT
|
|
|
Iagaru
A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G,
Nagpal S, Recht L, Gambhir SS.
Glioblastoma
Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2
PET/CT.
Radiology.
2015 Nov;277(2):497-506. doi: 10.1148/radiol.2015141550. Epub 2015
May 12.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
.
|
Unterrainer M, Fleischmann DF, Lindner S, Brendel M, Rupprecht R,
Tonn JC, Belka C, Bartenstein P, Niyazi M, Albert NL.
Detection
of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma
Using TSPO-PET With 18F-GE-180.
Clin Nucl Med. 2018
Jul;43(7):518-519. doi: 10.1097/RLU.0000000000002113.
Source
|
Abstract
| Full
text |
Similar
articles
|
|
|
FET-PET
IMAGING AND PREDICTION OF SITE OF RECURRENCE
|
|
.
|
Buchmann N, Gempt J.
In Reply to Letter to the Editor
Regarding "Can Early O-(2-18FFluoroethyl)-l-Tyrosine
Positron Emission Tomography After the Resection of a Glioblastoma
Predict the Location of Later Tumor Recurrence?"
World
Neurosurg. 2019 Jan 17. pii: S1878-8750(18)32841-9. doi:
10.1016/j.wneu.2018.12.019. [Epub ahead of print]
Source
| Full
text | Similar
articles
Referring
to: Fang X et al, Letter to the Editor Regarding “Can Early
Postoperative O-(2-18FFluoroethyl)-l-Tyrosine
Positron Emission Tomography After Resection of Glioblastoma
Predict the Location of Later Tumor Recurrence?” World
Neurosurg. 2019 Feb 26. pii: S1878875018323477. doi:
10.1016/j.wneu.2018.10.050. [Epub ahead of print] Source
,
Full
text
In
turn referring to: Buchmann N et al, Can Early Postoperative
O-(2-18FFluoroethyl)-l-Tyrosine
Positron Emission Tomography After Resection of Glioblastoma
Predict the Location of Later Tumor Recurrence? World Neurosurg.
2019 Jan;121:e467-e474. doi: 10.1016/j.wneu.2018.09.139. Epub 2018
Sep 27. Source
,
Full
text
|
|
|
.*
|
Buchmann N, Gempt J, Ryang YM, Pyka T, Kirschke JS, Meyer B,
Ringel F.
Can Early Postoperative
O-(2-18FFluoroethyl)-l-Tyrosine Positron
Emission Tomography After Resection of Glioblastoma Predict the
Location of Later Tumor Recurrence?
World Neurosurg.
2019 Jan;121:e467-e474. doi: 10.1016/j.wneu.2018.09.139. Epub 2018
Sep 27.
Source
| Full
text | Similar
articles
|
|
|
.
|
Fang X, Kong W, Yu Z, Qiu J, Duan H.
Letter to the Editor
Regarding “Can Early Postoperative
O-(2-18FFluoroethyl)-l-Tyrosine
Positron Emission Tomography After Resection of Glioblastoma
Predict the Location of Later Tumor Recurrence?”
World
Neurosurg. 2019 Feb 26. pii: S1878875018323477. doi:
10.1016/j.wneu.2018.10.050. [Epub ahead of print]
Source
| Full
text | Similar
articles
Referring
to: Buchmann N et al, Can Early Postoperative
O-(2-18FFluoroethyl)-l-Tyrosine
Positron Emission Tomography After Resection of Glioblastoma
Predict the Location of Later Tumor Recurrence? World Neurosurg.
2019 Jan;121:e467-e474. doi: 10.1016/j.wneu.2018.09.139. Epub 2018
Sep 27. Source
,
Full
text
|
|
|
FDG
PET/MR IMAGING COREGISTRATION
|
|
|
Leiva-Salinas
C, Schiff D, Flors L, Patrie JT, Rehm PK.
FDG
PET/MR Imaging Coregistration Helps Predict Survival in Patients
with Glioblastoma and Radiologic Progression after Standard of
Care Treatment.
Radiology.
2016 Oct 19:161172. doi: 10.1148/radiol.2016161172. [Epub ahead of
print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
RESPONSE
ASSESSMENT
|
|
|
Gahrmann
R,
van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de
Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B,
Smits M.
Comparison
of 2D (RANO) and volumetric methods for assessment of recurrent
glioblastoma treated with bevacizumab-a report from the BELOB
trial.
Neuro
Oncol. 2017 Feb 13. doi: 10.1093/neuonc/now311. [Epub ahead of
print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
Huang
R.
Response
assessment in high-grade glioma: tumor volume as endpoint.
Neuro
Oncol. 2017 Mar 30. doi: 10.1093/neuonc/nox035. [Epub ahead of
print]
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
Gliosarcoma
|
|
.
|
Peckham ME, Osborn AG, Palmer CA, Tsai A, Salzman KL.
Gliosarcoma: Neuroimaging and Immunohistochemical
Findings.
J Neuroimaging. 2019 Jan;29(1):126-132. doi:
10.1111/jon.12565. Epub 2018 Oct 8.
Source
| Full
text |
Similar
articles
|
|
|
|
|
